FBIO

Business Context and Reporting Period

Company: Fortress Biotech, Inc. (FBIO)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Fortress is a biopharmaceutical company focused on acquiring and advancing assets through a network of subsidiaries and partner companies. Key entities include Journey Medical Corporation (dermatology products), Cyprium Therapeutics (rare disease), and Mustang Bio (oncology). The company generates revenue primarily through product sales (Journey), royalties, and asset monetization.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 18% year-over-year, driven primarily by a 20% increase in product revenue from Journey Medical Corporation. Sales of Emrosi (rosacea treatment) rose significantly to $14.3 million in the first half of 2026 compared to $4.9 million in the prior year.
• Profitability Surge: The company reported a net income of $137.8 million, a reversal from a net loss of $36.3 million in the prior year. This was primarily due to a one-time gain on the sale of a Priority Review Voucher (PRV) of approximately $158.9 million recognized by Cyprium Therapeutics.
• Debt Reduction: Total notes payable decreased from $52.4 million to $39.6 million. Proceeds from the PRV sale were used to make a mandatory prepayment of $10.0 million plus accrued interest on the 2024 Oaktree Note, reducing the outstanding principal to $15.0 million.
• Deconsolidation Impact: The prior year period included Checkpoint Therapeutics until its acquisition by Sun Pharma in May 2025. The current period excludes Checkpoint, resulting in lower R&D and SG&A expenses compared to the prior year, though the gain on deconsolidation in 2025 was a significant non-recurring item.

Guidance, Outlook, and Risks

• Liquidity: Management states that current cash and cash equivalents ($153.8 million for the Parent Entity) are sufficient to fund operations for at least 12 months. However, the company expects to continue incurring operating losses from its core R&D activities and may require additional financing.
• Dividend Status: The Board has paused monthly dividends on the 9.375% Series A Preferred Stock since July 2024. As of June 30, 2026, approximately $16.0 million in dividends are accrued but undeclared. This pause renders the company ineligible to use Form S-3 for new equity offerings until dividends are paid.
• Key Risks:
  • Financing Constraints: Inability to raise capital due to the paused preferred dividends and reliance on Form S-1 or exempt offerings, which are more costly and time-consuming.
  • Product Concentration: Significant reliance on Journey Medical Corporation's dermatology products (Emrosi, Qbrexza, Accutane) for operating income. These products face generic competition and patent challenges (e.g., Lupin's Paragraph IV certification for Emrosi).
  • Regulatory & Clinical: Risks associated with the development of early-stage candidates (e.g., MB-109, ATX-04) and the potential for clinical trial failures or regulatory delays.

Investor Verification Checklist

• PRV Gain Sustainability: Verify that the $158.9 million gain from the Cyprium PRV sale is a non-recurring event and does not reflect core operational profitability.
• Preferred Dividend Arrears: Confirm the total accrued but undeclared dividends on Series A Preferred Stock ($16.0 million) and the timeline for potential resumption of payments.
• Debt Covenants: Review the amended 2024 Oaktree Agreement to ensure compliance with the reduced minimum liquidity covenant ($2.0 million) and the elimination of net sales covenants following the debt prepayment.
• Emrosi Patent Litigation: Monitor the status of the patent infringement lawsuit filed by Journey against Lupin regarding Emrosi, as a loss could accelerate generic competition.
• Cash Burn Rate: Assess the company's ability to fund R&D for subsidiaries (Mustang, Avenue, Helocyte) without access to the Form S-3 shelf registration.